Mumbai: Dabur Pharma has set up a marketing subsidiary company for direct sale of cancer treatment drugs in the US.
The setting up of the new company follows suspension of sales and distribution agreement with Hospira Inc on 5 May.
Dabur Pharma terminated the sales and distribution agreement between Dabur Oncology Plc and Hospira Inc for exclusive supply of oncology (cancer) products in the US, the company said in a filing with the Bombay Stock Exchange (BSE).
"Going forward, the company will sell and distribute its entire range of oncology products in US through its own infrastructure," the release said.
Dabur Oncology Plc, a wholly owned subsidiary of Dabur Pharma in UK, has incorporated the US subsidiary company for marketing oncology products, Dabur Pharma said in its release.
Dabur, meanwhile, received USFDA nod for selling two drugs - Paclitaxel and Carboplatin - in the US, which constitutes about 50 per cent of the global oncology market.
Dabur, a market leader in the oncology segment in India, sold its domestic non-oncology formulations business to Alembic Ltd early this year to focus on core oncology business.
The company is engaged in development and manufacture of active pharmaceutical ingredients, intermediates, and finished dosage forms. The company has manufacturing facilities in India and the UK.
Oncology is the branch of medicine that studies tumours (cancer) and seeks to understand their development, diagnosis, treatment, and prevention.